Alnylam Pharmaceuticals (ALNY) Cash & Current Investments (2009 - 2026)

Alnylam Pharmaceuticals has reported Cash & Current Investments for 18 years, with the latest figure at $3.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 193.05% year-over-year to $3.0 billion; the trailing twelve-month figure through Mar 2026 stood at $3.0 billion (up 193.05% YoY), and the FY2025 full-year result was $2.9 billion, up 197.75% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $3.0 billion, up from $2.9 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $3.0 billion in Q1 2026, with the low at $685.1 million in Q2 2023.
• Historically, Cash & Current Investments has averaged $2.0 billion across 5 years, with a median of $2.2 billion in 2022.
• Annual changes were most pronounced in 2023 — Cash & Current Investments slumped 67.06% — and 2024, when it surged 281.69%.
• Alnylam Pharmaceuticals' Cash & Current Investments stood at $896.7 million in 2022, then jumped by 170.8% to $2.4 billion in 2023, then slumped by 59.77% to $976.8 million in 2024, then surged by 197.75% to $2.9 billion in 2025, then advanced by 3.46% to $3.0 billion in 2026.
• The last three Cash & Current Investments figures came in at $3.0 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.7 billion (Q3 2025), per Business Quant data.